These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7955749)
1. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications. McGowan L Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749 [TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits. Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951 [TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer. Powell JL; Burrell MO; Kirchner AB South Med J; 1987 Dec; 80(12):1513-7. PubMed ID: 3423895 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging. Soper JT; Berchuck A; Clarke-Pearson DL Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171 [TBL] [Abstract][Full Text] [Related]
6. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. Klaassen D; Shelley W; Starreveld A; Kirk M; Boyes D; Gerulath A; Levitt M; Fraser R; Carmichael J; Methot Y J Clin Oncol; 1988 Aug; 6(8):1254-63. PubMed ID: 3045264 [TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429 [TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary. Peters WA; Smith MR; Cain JM; Lee RB; Yon JL Gynecol Oncol; 1992 Nov; 47(2):146-9. PubMed ID: 1468691 [TBL] [Abstract][Full Text] [Related]
9. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma. Wilkinson RH J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424 [TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer. Powell JL; Kirchner AB J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541 [No Abstract] [Full Text] [Related]
13. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients. Tulchinsky M; Eggli DF Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583 [TBL] [Abstract][Full Text] [Related]
14. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy. Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. Soper JT; Berchuck A; Dodge R; Clarke-Pearson DL Obstet Gynecol; 1992 Jun; 79(6):993-7. PubMed ID: 1579329 [TBL] [Abstract][Full Text] [Related]
16. Update on the role of radiotherapy in ovarian cancer. Lanciano R; Reddy S; Corn B; Randall M Semin Oncol; 1998 Jun; 25(3):361-71. PubMed ID: 9633849 [No Abstract] [Full Text] [Related]
17. Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites. Bakri YN; Given FT Am J Obstet Gynecol; 1984 Sep; 150(2):184-8. PubMed ID: 6476040 [TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications. Walton LA; Yadusky A; Rubinstein L Int J Radiat Oncol Biol Phys; 1991 May; 20(5):939-44. PubMed ID: 2022522 [TBL] [Abstract][Full Text] [Related]
19. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. A National Cancer Institute of Canada Clinical Trials Group Report. Klaassen D; Starreveld A; Shelly W; Miller A; Boyes D; Gerulath A; Levitt M Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1801-4. PubMed ID: 4044343 [TBL] [Abstract][Full Text] [Related]
20. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma. Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]